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Abstract: 
With the increase in incidence of type 1 diabetes (T1DM) there is an urgent need to 
understand the early molecular and metabolic alterations that accompany the autoimmune 
disease. This is not least because in murine models early intervention can prevent the 
development of disease. We have applied a liquid chromatography (LC-) and gas 
chromatography (GC-) mass spectrometry (MS) metabolomics and lipidomics analysis of 
blood plasma and pancreas tissue to follow the progression of disease in three models 
related to autoimmune diabetes: the non-obese diabetic (NOD) mouse, susceptible to the 
development of autoimmune diabetes, and the NOD-E (transgenic NOD mice that express 
the I-E heterodimer of the major histocompatibility complex II) and NOD- severe combined 
immunodeficiency (SCID) mouse strains, two models protected from the development of 
diabetes. All three analyses highlighted the metabolic differences between the NOD-SCID 
mouse and the other two strains, regardless of diabetic status indicating that NOD-SCID 
mice are poor controls for metabolic changes in NOD mice. Comparing NOD and NOD-E 
mice we show the development of T1DM in NOD mice is associated with changes in lipid, 
purine and tryptophan metabolism, including an increase in kynurenic acid and a decrease in 
lysophospholipids, metabolites previously associated with inflammation. 
 
Keywords: Non Obese Diabetic (NOD) mouse, NOD-severe combined immunodeficiency 
(SCID) mouse, mass spectrometry, xanthinine, kynurenic acid. 
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Introduction: 
Type 1 diabetes (T1DM) is increasing in prevalence across the globe, particularly in 
westernised countries with incidences of 8-17 per 100,000 people in Northern Europe and 
the US, and rising to 35 per 100,000 in Scandinavia 1,2. The disease arises following the 
destruction of beta cells in the pancreas, resulting from an autoimmune response, with 
sufferers having autoantibodies to the 65-kDa isoform of glutamic acid decarboxylase, zinc 
transporter proteins, phosphatase- related IA-2 molecule, insulin and islet cells 3. While not 
everyone with autoantibodies will progress to T1DM, the likelihood increases with the 
number of autoantibodies with 3-4 antibody types increasing the risk to ~80% 3. 
There is an important need for early stage biomarkers of the disease progression in T1DM in 
order to better understand the early aetiology of the disease and potentially target 
immunosuppression therapy to prevent the further destruction of pancreatic beta cells. 
Furthermore, there is significant evidence that immunomodulation by infection can be used 
to prevent T1DM if targeted to the right clinical window of autoimmunity 4,5. While 
autoantibodies do discriminate between type 1 diabetics and healthy individuals, 
autoantibodies are relatively late stage changes and do not always lead to beta cell 
destruction 3, confounding their use as reliable biomarkers  
Metabolomics, the study of the metabolite complement of a biofluid, cell, tissue or whole 
organism 6 has been previously used to follow both early and late stage changes in T1DM. 
Drug induced T1DM using streptozotocin induces a variety of metabolic changes in rodents 
including metabolites in the citric acid cycle, glucose metabolism, choline turnover and 
amino acid metabolism 7. These pathways have also been confirmed to be altered in 
humans with T1DM, and in particular insulin treatment has also been associated with protein 
turnover/amino acid metabolism and ketosis in healthy individuals in human intervention 
studies 8,9. In addition metabolomics has been used to discriminate type 1 diabetics with 
early stage kidney disease from those without10-12. However, these are late changes in the 
pathogenesis of T1DM and are unlikely to provide biomarkers of the pre-diabetic state. 
A sub-set of the field of metabolomics is lipidomics, which studies the lipid component of 
biofluids, cells or tissues. Lipidomics has been transformed by recent developments in liquid 
chromatography mass spectrometry (LC-MS) which allows the rapid analysis of intact lipids 
from a range of chemical classes including triglycerols, diglycerols, phospholipids, free fatty 
acids, cholesterol and cholesterol esters and sphingolipids 13. Metabolomics and lipidomics 
have been used to also follow early stage disease progression in both mouse models and 
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human sufferers with T1DM 14-18. Examining serum from children who subsequently went on 
to develop T1DM, Oresic and colleagues 14 identified a number of early stage metabolic 
changes, including reduced concentrations of succinate, phosphatidylcholines and 
triglycerides at birth. In addition, prior to serum conversion in terms of autoantibodies, 
individuals had increased pro-inflammatory lysophosphocholines, and reduced 
concentrations of triglycerides and anti-oxidant ether lipids. Metabolic changes have even 
been detected in the cord blood of babies that subsequently developed T1DM before the 
age of 8 17. 
In the present study we have profiled metabolic and lipidomic changes in a mouse model of 
autoimmune diabetes. The non-obese diabetic (NOD) inbred mouse strain recapitulates the 
autoimmune nature of T1DM in humans and has allowed researchers to follow the 
autoimmune destruction of beta cells in the pancreas as well as develop treatments that halt 
this process 19. The mouse develops islet infiltration (insulitis) at around 3-4 weeks 
comprising initially of innate immune cells such as macrophages and dendritic cells followed 
by T cells and other cells of the immune system20-23 22-24. The mice develop diabetes from 
around 14 weeks of age. This mouse model has been used previously to monitor metabolic 
changes that accompany the progression of T1DM 16, but in this previous study only NOD 
mice were considered, and thus, it is difficult to determine what changes were associated 
with disease progression and what was associated with age-related changes in the 
pancreas. In the present study we have compared metabolic changes in NOD mice with their 
transgenic control strain NOD-E mice. The NOD-E mouse is a transgenic mouse generated 
directly on the NOD background which, unlike the NOD mouse, expresses the major 
histocompatibility complex (MHC) class II I-E heterodimer 25. These mice are protected from 
the development of T1DM and develop negligible insulitis. In the present study we show by 
metabolomics that the NOD-E mouse is a better control for the metabolic changes 
associated with the NOD mouse compared with the NOD severe combined 
immunodeficiency (SCID) mouse strain 26. 26. As the NOD-SCID mouse was generated 
through breeding the SCID mutation onto the NOD mouse background using donor SCID 
mice from a different genetic background there may be contributions from non-NOD genes in 
this strain. In addition NOD and NOD-E mice have distinct metabolic trajectories during the 
ageing process, while aged NOD mice that do not develop T1DM develop a metabolic 
phenotype more similar to NOD-E mice than NOD mice. 
   
Experimental Procedures: 
Animal Experiments: 
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All mice were obtained from stable colonies housed within the Department of Pathology, 
University of Cambridge. The incidence of diabetes in NOD female mice in this colony is 
around 80%. Further details as the progression of the disease process are found in the 
supplementary section. Mice were housed in a temperature- and humidity-controlled facility, 
with a 12-h:12-h light-dark cycle and access to water and regular chow diet (Caloric content: 
11.5% fat, 26.9% protein, 61.6% carbohydrate; RM1; Special Diet Services, UK) ad libitum. 
Blood plasma was collected by retro-orbital bleed into heparinised vials prior to 
centrifugation. The pancreas was rapidly dissected and a portion of each tissue was snap 
frozen with liquid nitrogen and stored at -80 oC until further analysis. All animal work was 
carried out in accordance with UK Home Office project and personal licences (80/2442 and 
70/8442) and was approved by the Ethical Review Committee of the University of 
Cambridge.  
 
Two studies were performed. The first examined blood plasma and pancreatic tissue taken 
post mortem from stable colonies of female NOD, NOD-E and NOD-SCID mice 
(Supplementary Table 1). In the second study blood plasma was sampled at six time points 
(6, 9, 11, 14, 19, and 22 weeks) for female NOD (n=9), NOD-E (n=7) and NOD-SCID mice 
(n=10) (Supplementary Table 2). In this study pancreas tissue was taken at the end of the 
study. 
Analysis of the metabolite composition of faeces 
To assess changes in the gut metabolome mouse faeces were collected from individual 
NOD (n=5 for 6 weeks age and n=6 each for 12 and 18 weeks age) and NOD-E mice (n=5 
for 6 and 12 weeks age). 20 mg of faeces were extracted using the chloroform/methanol 
extraction procedure described below. 
 
Metabolite extraction from the pancreas, blood plasma and faeces 
Metabolites (50 µl plasma or 50 mg tissue wet weight) were extracted using a modified Bligh 
and Dyer method 27. 600 µl of methanol:chloroform (2:1 v/v) was added to each sample, with 
tissue samples then being pulverized/homogenised using a TissueLyser (Qiagen, Hilden, 
Germany) set at 20 Hz for 20 minutes and sonicated for 15 minutes. 200 µl of chloroform 
and 200 µl of H2O (Chromasolv® Plus for HPLC, Sigma-Aldrich, Gillingham, UK) were 
added, vortex mixed, and centrifuged at 17,000 rcf for 15 minutes. The aqueous and organic 
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layers were then separated. The procedure was repeated to form a double extract to 
maximise the recovery of metabolites from the protein pellet. The aqueous layer was dried 
overnight in an evacuated centrifuge (Eppendorf, Hamburg, Germany), while the lipid 
fraction was dried under a stream of nitrogen gas. Dried samples were stored at -80 °C until 
analysis. 
 
Lipidomics analysis of blood plasma and pancreas tissue 
All solvents used were of LC-MS grade or better and ordered from Sigma Aldrich 
(Gillingham, UK). All internal standards were obtained from Avanti Polar Lipids (Alabaster, 
AL, USA) with the exception of undecanoic acid and trilaurin (Sigma Aldrich). 
The samples, QC samples (pools of either the plasma and pancreas extracts) and blanks 
were placed in a pre-defined random order across 96-well plates (Plate+, Esslab, Hadleigh, 
UK). The extracts were reconstituted in 100 µl of 7.5 mM NH4Ac IPA:MeOH (2:1), spiked 
with six internal standards (1,2-di-o-octadecyl-sn-glycero-3-phosphocoline, 1,2-di-O-
phytanyl-sn-glycero-3-phosphoethanolamine, C8-ceramide, N-heptadecanoyl-D-erythro-
sphingosylphosporylcholine, undecanoic acid, and trilaurin) which were used to correct for 
variations in m/z across the dataset acquired. 
Lipidomics was performed on the extract using chip-based nanospray with an Advion 
TriVersa Nanomate (Advion, Ithaca, USA) interfaced to the Thermo Exactive Orbitrap 
(Thermo Scientific, Hemel Hampstead, UK), using a mass acquisition window from 200 to 
2000 m/z and acquisition in positive mode. A voltage of 1.2 kV was used in positive mode 
with an acquisition time of 72 s. 
Acquired spectral raw data were processed using an in-house bioinformatics platform based 
on XCMS 28. This performed sample-specific mass re-calibration using predefined sets of 
internal standards and the removal of commonly present contaminant ions (often associated 
with plasticizers) with help of predefined rejection lists and mass defect filters. The raw data 
were converted to .mzXML (using MSconvert 29 with peakpick level 1), parsed with R and 50 
(scan from 20 to 70) spectra were averaged per sample using XCMS 28, with a signal cutoff 
at 2000. The files were aligned using the XCMS 28,30 grouping function using “mzClust” with 
a m/z-window of 22 ppm and a minimum coverage of 60 %. Isotopes were annotated using 
the CAMERA package in R with the following parameters (maxcharge=1, ppm=5, 
mzabs=0.001, intval = c("into"), minfrac=0.25) 30. 
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Automated compound annotation was carried out using both an exact mass search in 
compound libraries as well as applying the referenced Kendrick mass defect approach. 
Signal normalisation was performed by summing the intensities of all detected metabolites to 
a fixed value to produce a correction factor for the efficiency of ionisation. Features of 
interest were subsequently confirmed using fragmentation experiments on a Thermo Velos 
Orbitrap mass analyser using an Advion Nanomate to directly infuse the lipid extract or a 
Surveyor HPLC system for chromatographic separation. The selected masses were isolated 
with a 1.5 m/z width in the linear ion trap and then fragmented using either linear ion trap 
with 35% relative collision energy or in the HCD (higher-energy collision-induced 
dissociation) collision cell, with a range of collision energies from 5% to 75% relative collision 
energy. All spectra were recorded in the Orbitrap set at 100,000 resolution. As fragmentation 
data confirms the fatty acids that are present but does not definitively define where the 
double bonds are placed these annotations are at level 2 of the Metabolomics Standards 
Initiative 31. 
Targeted analysis of aqueous metabolites in blood plasma, pancreas and faeces 
All analyses were carried out using a QTRAP 4000 quadrupole mass spectrometer  (AB 
Sciex, Warrington, UK) coupled to an Acquity ultra performance liquid chromatography 
(UPLC) system from Waters Ltd. (Atlas Park, Manchester, UK) according to published 
methods 32,33. In brief, formic acid, ammonium acetate, and valine-d8 were purchased from 
Sigma-Aldrich. Plasma samples were prepared for LC-MS analyses via protein precipitation 
with the addition of nine volumes of 74.9:24.9:0.2 vol/vol/vol acetonitrile/methanol/formic acid 
containing stable isotope-labeled valine-d8 internal standard. The valine-d8 standard was 
used to calculate concentrations for the endogenous metabolites measured by this method. 
The samples were centrifuged (10 min, 15,000 g, 4 °C), and the supernatants were injected 
directly. Two columns were used for chromatography: i. an Atlantis HILIC silica 3 µm 2.1 × 
150 mm column (Waters Corporation) at 30 °C using 0.1 % formic acid and 10 mM 
ammonium formate as solvent A and 0.1 % formic acid in acetonitrile as solvent B, at 250 
uL/min across a 32 min chromatography run time and ii. a Synergi 4u Polar-RP 80A 4µm 4.6 
× 50 mm column (Phenomenex) at 30 °C using 95% water, 5% acetonitrile and 5 mM 
ammonium acetate as solvent A and 5% water, 95% acetonitrile and 5 mM ammonium 
acetate as solvent B, at 250 uL/min across a 15 min chromatography run time. This method 
detected the following metabolites: glycine, alanine, serine, threonine, methionine, aspartate, 
glutamate, asparagine, glutamine, histidine, arginine, lysine, valine, leucine, pheylalanine, 
tyrosine, tryptophan, proline, cis/trans hydroxyproline, ornithine, citrulline, taurine, 5-HT, 5-
HIAA, serotonin, cysteamine, aminoisobutyric acid, dimethylglycine, homocysteine, 
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argininosuccinate, ADMA/SDMA, allantoin, GABA, anthranilic acid, carnitine, kynurenic acid, 
1-methylhistamine, 5'-adenosylhomocysteine, carnosine, histamine, 3-hydroxyanthranilic 
acid, N-carbomoyl-beta-alanine, cobalamin, thiamine, niacinamide, betaine, choline, 
phosphocholine, phosphoethanolamine, alpha-glycerophosphocholine, acetylcholine, 
spermidine, creatine, creatinine, thyroxine, trimethylamine-N-oxide, glucose, adenosine, 
cytosine, thymidine, xanthosine, 2'-deoxycytidine, isoleucine, xantherenate, kynurenine, 
beta-hydroxyisovaleric acid, adenine, AMP, cGMP, CMP, guanine, guanosine, methyl-
cytosine, PEP, SAH, uracil, cystathionine, histidinol, N-acetyl-glutamate, N-acetyl-glutamine, 
glucosamine-6-phosphate, IDP and indole. As metabolite identification was confirmed with 
respect to genuine standards this is a level 1 identification according to the Metabolomics 
Society Metabolomics Standards Initiative 31. 
 
Total plasma fatty acid analysis using fatty acid methyl esters by Gas Chromatography –
Mass Spectrometry of blood plasma, pancreas and faeces  
Total fatty acid analysis was performed as described in 34.The organic fraction was dissolved 
in methanol:chloroform (750 µl,  ratio 1:1) and D25-tridecanoic acid in chloroform (internal 
standard, at 200 µM, 50 µl; Sigma Aldrich) was added. Acid-catalyzed esterification was 
used to derivatize the organic phase samples. BF3-methanol (10%, 0.125 ml; Sigma-Aldrich) 
was added to the organic phase and incubated at 90 °C for 90 minutes. Water (0.15 ml) and 
hexane (0.3 ml) were added and the samples vortex mixed for 1 minute and left to form a 
bilayer. The aqueous phase was discarded and the organic layer, containing fatty acid 
methyl esters (FAMEs), evaporated to dryness under a stream of nitrogen prior to 
reconstitution in analytical grade hexane (100 µl; Sigma-Aldrich) before gas chromatography 
mass spectrometry (GC-MS) analysis.  
 
GC-MS was performed using a Trace GC Ultra coupled to a Trace DSQ II mass 
spectrometer (Thermo Scientific, Hemel Hempstead, UK). The derivatized organic samples 
were injected with a split ratio of 20 onto a 30 m × 0.25 mm 70% cyanopropyl 
polysilphenylene-siloxane 0.25 µm TR-FAME stationary phase column (Thermo Scientific). 
GC-MS chromatograms were processed using Xcaliber (version 2.0; Thermo Scientific). 
Each individual peak was integrated and then normalized to total intensity of the FAMEs 
detected. Overlapping peaks were separated using traces of single ions. Peak assignment 
was based on mass fragmentation patterns matched to the National Institute of Standards 
and Technology (USA) library and to previously reported literature. Identification of 
metabolites from organic phase GC-MS analysis was supported by comparison with a FAME 
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standard mix (Supelco 37 Component FAME Mix; Sigma-Aldrich) and retention time 
matching. As metabolite identification was confirmed with respect to genuine standards this 
is a level 1 identification according to the Metabolomics Society Initiative 31. 
 
Univariate statistical analysis 
Univariate statistical tests including Student’s t-test and ANOVA were performed with Matlab 
(Mathworks) using the Statistical Toolbox, with the exception of Pearson correlation plots 
which were performed within the statistics package R (www.r-project.com) as described in 35. 
For univariate statistics a Bonferonni correction was applied to correct for multiple testing. 
 
Multivariate statistical analysis 
 
The metabolic profiles obtained, containing integral information, were analysed using the 
multivariate statistical analysis tools found in SIMCA (version 13; Umetrics AB, Umeå, 
Sweden). Models were processed using principal components analysis (PCA; an 
unsupervised technique), partial least squares discriminate analysis (PLS-DA; a supervised 
classification), orthogonal partial least squares discriminate analysis (OPLS-DA; a 
supervised classification) and orthogonal partial least squares (O-PLS; a multivariate 
regression tool used with age set as the y-variable) where appropriate. Lipidomics data were 
Pareto scaled, in which each variable was centred and multiplied by 1/(Sk)
1/2 where Sk is the 
standard deviation of the variable. GC-MS total fatty acid data and targeted analysis of 
aqueous metabolites were unit variance scaled. Model statistics reported include the fraction 
of the sum of squares for the selected component (R2) which equates to the percentage of 
the model variance explained, and the predictive ability (Q2). Cross-validation was performed 
to test whether models were over fitted. For PLS-DA models random permutation was used 
whereby the class membership of individual samples are permutated randomly. In addition 
ANOVA of the cross-validated residuals (CV-ANOVA) test was performed within Simca to 
further validate the models 36. Where relevant OPLS-DA models were further validated by 
selecting 2/3 of the data randomly and then predicting the class membership of the other 
1/3.  
 
Results: 
Lipidomics of blood plasma: 
Blood plasma from both the cross sectional study and time course study were analysed 
using direct infusion (DI-)MS in positive ion mode (Figure 1a). 250 variables were detected 
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across the dataset and these were imported into the multivariate models. Initially, the 
samples from the NOD, NOD-E and NOD-SCID mice were compared. OPLS-DA readily 
separated the three mouse genotypes according to their lipidomic profiles, regardless of age 
(Figure 1b; for summary statistics see figure legend). This model was improved by a two 
group comparison where the NOD-SCID mice were compared with a combined group of 
NOD and NOD-E mice (Figure 1c). This was in part driven by the greater long chain 
containing triglycerides in the two NOD strains, particularly TAG(58:9) (exact mass(m/z): 
946.789), TAG(62:14) (m/z = 992.772), TAG(58:10) (m/z = 944.773), TAG(60:11) (m/z = 
970.790), TAG(58:11) (m/z = 942.757), TAG(58:8) (m/z =  948.805), TAG(60:12) (m/z = 
968.773), TAG(60:10) (m/z = 972.805), TAG(56.9) (m/z = 918.756) and TAG(60:9) (m/z = 
974.821). To test the validity of the model further, an OPLS-DA model was built using 2/3 of 
the data and then predicting the class membership of the remaining third. This correctly 
picked the classification of 87% of the data. 
Removing the NOD-SCID group from the dataset, and comparing the NOD and NOD-E mice 
for those aged 4-23 weeks, OPLS-DA discriminated the two mouse strains (Figure 1d). 
NOD-E were characterised by increased concentrations of cholesterol esters and 
lysophosphatidylcholines (Table 1 for list of metabolite changes) while NOD mice had higher 
concentrations of a range of triglycerides and diglycerides (Table 1). To test the validity of 
the model further, an OPLS-DA model was built using 2/3 of the data and then predicting the 
class membership of the remaining third. This correctly picked the classification of 71% of 
the data. 
Considering the time course of the development of type 1 diabetes in the NOD mice, the 
lipidomics data for the NOD and NOD-E mice was next examined looking at mice less than 
14 weeks and mice aged 14 weeks and above. For mice less than 14 weeks, OPLS-DA 
separated the two genotypes, although the model was relatively weak (Figure 1e). This 
classification was caused by increases in ceramides, cholesterol esters and lyso-
phophatidylcholines and three unknown lipids (m/z = 642.619), (m/z = 590.323) and (m/z = 
909.548) in NOD-E mice, and triglycerides and an unknown lipid (m/z = 577.520) in NOD 
mice (Table 1). A more robust OPLS-DA model was built for mice aged 14 weeks and older 
(Figure 1f). However, the distinct pattern between cholesterol esters and lyso-phospholipids 
versus triglycerides found in the overall NOD compared with NOD-E mice comparison, and 
the younger mice was no longer apparent at this later time point (Table 1). 
Next we compared lipidomic profiles of NOD mice aged 25-30 weeks who had not 
developed T1DM (NOD* group) with the NOD and NOD-E lipidomic profiles used in the 
previous comparisons. No model could be built that discriminated that NOD* group from the 
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NOD-E mice, indicating they shared a common metabolic profile. However, the NOD and 
NOD* group was separated by OPLS-DA (Figure 1g). To further investigate these profiles, 
the NOD* group was mapped onto the NOD and NOD-E OPLS-DA model in Figure 1d. 
Using this model to classify the NOD* group, 10/10 samples were classified with the NOD-E 
group, with the average predicted Y = 0.84 ± 0.14, where Y=1 is a perfect classification as a 
NOD-E mouse and Y= 0 is a perfect classification as a NOD mouse. 
Table 1: Summary of metabolite changes for NOD and NOD-E comparisons described in 
Figure 1. Key: CE cholesterol ester, LPC lysophosphatidylcholine, TAG triacylglycerols, DI-
MS direct infusion mass spectrometry, QqQ triple quadrupole mass spectrometry. MSI 
Metabolomics Standardisation Initiative for metabolite identification.   
Comparison Increased in NOD Increased in NOD-E Method Adduct Mass or mass 
transition 
MSI level 
assignment 
All NOD v 
NOD-E 
 
 
 
 
 
 
 
 
 
 
TAG(56:8)  
TAG(52:6) 
TAG(54:4)  
TAG(52:3)  
TAG(53:4)  
TAG(58:10)  
TAG(54:7)  
TAG(54:5)  
TAG(52:5)  
DAG(41:4)  
TAG(54:6)  
TAG(52:4)  
Argininosuccinate 
cobalamin 
creatinine  
AMP  
kynurenic acid 
CE(16:1)  
LPC(20:4)  
LPC(22:6)  
CE(18:1)  
LPC(22:6)  
LPC(18:2)  
LPC(18:1) 
CE(16:0)  
PC(34:3)  
CE(18:4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serotonin 
5-hydroxytryptophan 
phosphoethanolamine 
phosphoenolpyruvate 
Ornithine 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
QqQ 
QqQ 
QqQ 
QqQ 
QqQ 
QqQ 
QqQ 
QqQ 
QqQ 
QqQ 
[M+H]
+ 
[M+H]
+ 
[M+H]
+ 
[M+H]
+ 
[M+H]
+ 
[M+H]
+ 
[M+H]
+ 
[M+H]
+ 
[M+H]
+ 
[M+H]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+
 
649.603 
544.340 
568.340 
668.634 
590.323 
520.340 
522.356 
642.619 
756.555 
645.559 
920.772 
868.740 
900.804 
874.788 
886.788 
944.773 
894.756 
898.788 
870.756 
704.636 
896.772 
872.772 
291→70 
678→147 
114→44 
134→107 
190→144 
177→160 
221→204 
142→44 
168→ 
133→70 
2 
2 
2 
2  
2 
2 
2 
2 
2 
2 
2 
2 
2 
2  
2 
2 
2 
2 
2 
2 
2 
2 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
 
Young NOD 
v NOD-E 
(less than 
14 weeks) 
 
 
 
 
 
 
TAG(52:3) 
TAG(51:3)  
TAG(52:4)  
TAG(52:5)  
TAG(52:6)  
(Cer(t40:0)  
Cer(t42:0)  
CE(18:4)  
CE(20:4)  
(LPC(20:4)  
LPC(22:6) 
 
 
 
 
 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
[M+H]
+ 
[M+H]
+ 
[M+H]
+ 
[M+H]
+ 
[M+H]
+ 
[M+H]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
640.604 
668.633 
645.559 
673.590 
544.340 
568.340 
874.788 
860.772 
872.772 
870.756 
868.740 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
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TAG(54:5)  
TAG(54:7)  
TAG(50:4)  
TAG(54:6)  
Arginosuccinate 
Cobalamin 
creatine 
 
 
 
 
 
 
 
5-hydroxytryptophan 
Serotonin 
phosphoenolpyruvate 
Phosphoethanolamine 
ornithine 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
QqQ 
QqQ 
QqQ 
QqQ 
QqQ 
QqQ 
QqQ 
QqQ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
898.788 
894.756 
844.741 
896.772 
291→70 
678→147 
132→90 
221→204 
177→160 
168→ 
142→44 
133→70 
2 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
Old NOD v 
NOD-E (14 
weeks and 
older) 
 
 
 
 
 
 
 
 
 
CE(20:4) 
LPC(20:3)  
Cer(t43:1) 
LPC (18:0) 
CE(20.4)  
AMP 
Cobalamin 
Arginosuccinate 
TAG(56:6)  
PC(32:0)  
TAG(50:2)  
TAG(56:7)  
TAG(52:3)  
TAG(50:1)  
DG (O-34:3)  
TAG(50:3)  
LPC(22:6) 
 
 
 
 
 
 
 
 
Serotonin 
5-hydroxytryptophan 
phosphoenolpyruvate 
Phosphoethanolamine 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
DI-MS 
QqQ 
QqQ 
QqQ 
QqQ 
QqQ 
QqQ 
QqQ 
[M+NH4]
+ 
[M+H]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+NH4]
+ 
[M+H]
+ 
[M+H]
+ 
[M+H]
+ 
[M+H]
+ 
[M+H]+ 
[M+Na]+
 
 
 
924.807 
734.570 
848.772 
922.789 
874.788 
850.789 
577.520 
846.756 
568.340 
690.620 
546.354 
680.635 
524.372 
695.575 
134→107 
678→147 
291→70 
177→160 
221→204 
168→ 
142→44 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
1 
1 
1 
1 
1 
1 
1 
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Figure 1: A: High resolution mass spectrum of a typical lipid extract from blood plasma 
derived from the NOD mouse. B. OPLS-DA plot of lipidomics of blood plasma from NOD, 
NOD-E and NOD-SCID mice considered as separate groups. Data is Pareto scaled. R2(X) = 
75%, R2(Y) = 48%; Q2 = 34%; p = 3.5*10-22 by CV-ANOVA for cross validation. 2 
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components and 6 orthogonal components. C. OPLS-DA plot of lipidomics of blood plasma 
from NOD-SCID mice compared with a combined group of NOD and NOD-E mice (labelled 
Both). Data is Pareto scaled. R2(X) = 69%; R2(Y) = 68%; Q2 = 51%; p = 5.8*10-34. 1 
component and 6 orthogonal components. D. OPLS-DA plot of lipidomics of blood plasma 
from NOD and NOD-E mice. Data is Pareto scaled. R2(X) = 57%, R2(Y) = 41%, Q2 = 23%; p 
= 5.4*10-9, 1 component and 3 orthogonal components. E. OPLS-DA plot of lipidomics of 
blood plasma from NOD and NOD-E mice under 14 weeks of age. Data is Pareto scaled. 
R2(X) = 43%, R2(Y) = 32%, Q2 = 23%, p = 1.2*10-7, 1 component and 1 orthogonal 
component. F. OPLS-DA plot of lipidomics of blood plasma from NOD and NOD-E mice 
aged 14 weeks and over. Data is Pareto scaled. R2(X) = 56%, R2(Y) = 80%, Q2 = 54%; 
p=2.2*10-5, 1 component and 4 orthogonal components. G. OPLS-DA plot of lipidomics of 
blood plasma from NOD (diabetic) and NOD (non-diabetic referred to as NODSTAR) mice 
aged 25-30 weeks and over. R2(X) = 68%; R2(Y) = 79%; Q2 = 56%; p = 2.5*10-11, 1 
component and 4 orthogonal components. 
To explore the lipidomic changes further, total fatty acid analysis was performed using GC-
MS. Examining the different mouse strains, a model could be built that discriminated the 
three mouse strains (Figure 2a), regardless of age of animal, with again the NOD-SCID 
mice being the most different from the other two mouse strains. To explore this difference 
further, the NOD-SCID mice were compared with the other two strains treated as a single 
group. This produced a more robust model (Figure 2b), with NOD-SCID mice having higher 
concentrations of C16:0, C21:0, C20:5, and C18:3 and decreased concentrations of C16:2, 
C24:1, C17:0 and C14:0. Similar fatty acid changes were also observed in the Pareto scaled 
model as evidenced in the associated S-plot (Figure 2c). To test the validity of the model 
further, an OPLS-DA model was built using 2/3 of the data and then predicting the class 
membership of the remaining third. This correctly picked the classification of 88% of the 
data. However, NOD and NOD-E mice regardless of age could not be separated according 
to their total fatty acid profile (data not shown). Similarly no model could be built that 
discriminated NOD from NOD-E mice when considering animals 14 weeks and over of age, 
or when considering the animals under 14 weeks of age. 
Finally we examined whether we could model time changes in either the NOD or NOD-E 
mice using PLS to regress age of animal against metabolic profiles. A robust model was built 
for regressing the blood plasma profile of NOD mice against age (Figure 2d shows the 
actual verses predicted age of mice according to the total fatty acid profile of the blood 
plasma). This was caused by increases in C18:3, C18:2, and C20:4, and decreases in 
C16:1, cholesterol, C22:0, and C20:3 as the animals age. However, no model could be 
produced for the NOD-E mice that passed cross validation. 
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Figure 2: A. OPLS-DA plot of total fatty acid analysis of blood plasma from NOD, NOD-E 
and NOD-SCID mice considered as separate groups. Data is Univariate scaled. R2(X) = 
25%; R2(Y) = 47%; Q2 = 33%, 2 components and 1 orthogonal component. B. OPLS-DA plot 
of total fatty acid analysis of blood plasma from NOD-SCID mice compared with a combined 
group of NOD and NOD-E mice (labelled Both). Data is univariate scaled. R2(X) = 40%; 
R2(Y) = 80%; Q2 = 72%; p = 6.3*10-37, 1 component and 3 orthogonal components. C. S-plot 
of Pareto scaled variables from the dataset analysed for the plot in B. D. PLS plot of age 
against metabolic profile of NOD mice. Q2 = 51%, R2(X) = 27%, R2Y = 77%; p=4*10-6, 1 
component and 2 orthogonal. 
 
 
 
Alterations in amino acid metabolism in blood plasma 
LC-MS/MS was used to profile amino acids and nucleotides using a targeted method of 87 
metabolites in blood plasma and then multivariate statistics was used to identify clusters 
within the dataset in terms of comparing different mouse genotypes, as well as exploring 
time trends by regressing age of animal against metabolic profile. Initially, the three mouse 
strains were compared regardless of age. OPLS-DA readily discriminated all three groups 
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according to genotype, with NOD-SCID mice most separated along the first component 
compared with the other two animal models (Figure 3a). Similarly to the lipidomic data, a 
more robust model could be built separating the NOD-SCID mice from the other two strains 
(Figure 3b). To test the validity of the model further, an OPLS-DA model was built using 2/3 
of the data and then predicting the class membership of the remaining third. This correctly 
picked the classification of 92% of the data. This separation was driven by increases in 
trimethylamine-N-oxide, kynurenine, 1-methyl-histidine, xanthosine and lysine and 
decreases in cobalamin, betaine, β-hydroxyisovaleric acid, acetylcholine and inosine 
diphosphate in the NOD-SCID mice (Figure 3c). Taking the metabolites with a Variable 
Importance Parameter >1 from this model, metabolites involved in nucleotide metabolism, B-
vitamins, one-carbon metabolism/choline breakdown and amino acids were responsible for 
this discrimination (Supplementary Table 3). Using the metabolite enrichment software on 
MetaboAnalyst 37 the most perturbed pathways were glycine, serine and threonine 
metabolism, biotin/thiamine metabolism, beta-alanine metabolism, tryptophan metabolism 
and protein biosynthesis. 
Underlying the large differences between NOD-SCID mice and the other two strains, a 
weaker model was produced examining NOD and NOD-E mice, regardless of age. OPLS-
DA produced a one component model with three orthogonal components with a Q2 = 50% 
indicating the separation was less marked than models involving the NOD-SCID strain 
(Figure 3d). To test the validity of the model further, an OPLS-DA model was built using 2/3 
of the data randomly selected and then predicting the class membership of the remaining 
third. This correctly picked the classification of 83% of the data. This was associated with an 
increase in the concentrations of argininosuccinate, cobalamin, creatinine, AMP and 
kynurenic acid in NOD mice and a relative increase in concentration of serotonin, 5-
hydroxytryptophan (5-HT), phosphoethanolamine, phosphoenolpyruvate and ornithine in 
NOD-E mice (Figure 3e). While better models could be built considering mice aged below 
14 weeks (Figure 3f) and over 14 weeks (Figure 3g), similar metabolites drove all three 
models (Figure 3e & 3h). 
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Figure 3: A. OPLS-DA plot of targeted analysis of central metabolism (amino acids, TCA 
cycle intermediates, nucleotides, and other small aqueous metabolites) of blood plasma from 
NOD, NOD-E and NOD-SCID mice considered as separate groups. Data is Univariate 
scaled. R2(X) = 56%, R2(Y) = 72%, Q2 = 52%, 2 components and 4 orthogonal components; 
CV ANOVA validation p = 1.5*10-22. B. OPLS-DA plot of targeted analysis of central 
metabolism of blood plasma from NOD-SCID mice compared with the NOD and NOD-E 
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mice as a single group. R2(X) = 42%, R2(Y) = 79%, Q2 = 79%, 1 component and 2 
orthogonal components; CV-ANOVA validation p = 2.7*10-38. C. Variable Importance 
Parameter (VIP) plot to show key metabolites that are most important for the discrimination 
for the plot in B. D. OPLS-DA plot of targeted analysis of central metabolism of blood plasma 
from NOD and NOD-E mice. Data is Univariate scaled. R2(X) = 51%; R2(Y) = 76%; CV-
ANOVA validation p = 2*10-10. E. VIP plot to show key metabolites that are most important 
for the discrimination for the plot in D. F. OPLS-DA plot of targeted analysis of central 
metabolism of blood plasma from NOD and NOD-E mice below 14 weeks of age. Data is 
Univariate scaled. R2(X) = 44%, R2(Y) = 84%, Q2 = 74%, 1 component and 2 orthogonal 
components; CV ANOVA validation p = 2.7*10-38. G. OPLS-DA plot of targeted analysis of 
central metabolism of blood plasma from NOD and NOD-E mice 14 weeks and older of age. 
Data is Univariate scaled. R2(X) = 64%, R2(Y) = 82%, Q2 = 51%, 1 component and 4 
orthogonal components; CV-ANOVA validation p = 2.7*10-38. H. SUS-plot of discriminatory 
metabolites for models described in F and G.  
 
For both non-diabetic and diabetic NOD mice, and NOD-E mice robust PLS models could be 
built between amino acid profiles and age of animal. For the non-diabetic NOD mice, age 
was associated with an increase in 5-hydroxytryptophan (p = 0.017; One-way ANOVA), 
serotonin (p = 0.013), creatinine (p < 0.0001), histamine (p = 0.0002) and cytosine (p < 
0.0001) and decreases in dimethylglycine (p = 0.0072) and hydroxyproline (p=0.005) 
producing a robust PLS model (Figure 4a). Repeating this analysis with the diabetic NOD 
mice another highly predictive model was again built between age and amino acid profiles 
(R2X = 45%, R2Y = 97%; Q2 = 78%; data not shown). As with the non-diabetic animals, 
ageing was associated with a decrease in hydroxyproline (p = 0.0002 using one-way 
ANOVA). In addition, ageing of the non-diabetic NOD animals was associated with a 
decrease in arginine (p = 0.004), glycerophosphocholine (p < 0.0001) and lysine (p = 0.006) 
and increased in trimethylamine-N-oxide (p<0.0001), kynurenic acid (p < 0.0001), 
phenylalanine (p = 0.0005), glutamine (p = 0.0003) and alanine (p < 0.0001) (data not 
shown).  
Similarly a robust PLS model was also built for NOD-E mice (Q2 = 72%, R2X = 46%, R2Y = 
92%). As with the NOD mice, ageing was associated with a decrease in hydroxyproline (p < 
0.0001 one-way ANOVA) and an increase in creatinine (p < 0.0001). In addition across the 
ageing time course there was a decrease in xanthosine (p < 0.0001) and increases in the 
concentration of tryptophan (p = 0.0001), thiamine (p < 0.0001), creatine (p = 0.0002), and 
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indole (p = 0.0003). In all three models the use of SUS plots demonstrated that the 
metabolic effects of ageing were similar across all three mouse groups (Figure 4b). 
 
 
Figure 4. A: PLS model of targeted analysis of central metabolism of blood plasma from 
NOD mice against age (R2X = 53%, R2Y = 79%, Q2 = 65%). B: SUS-plot of PLS models for 
NOD mice and NOD-E mice against age. In this plot the loadings for the two PLS models are 
plotted against each other so that if the two models had the same loadings then these would 
line up at 45° to the x and y-axes. While some metabolites are in common there is also a 
degree of scatter from the 45° line showing that other metabolites are responsible for the 
ageing trends in the NOD and NOD-E mice. 
 
One of the major pathways to be perturbed between the three strains of mice and across the 
ageing studies was the tryptophan metabolism pathway (KEGG map 00380). To investigate 
this further we constructed correlation plots between tryptophan and its products detected in 
the targeted assay for NOD and NOD-E mice (Figure 5a). For both strains tryptophan was 
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highly correlated with the majority of metabolites, as might be expected by the major 
precursor to many of these metabolites (Figure 5b). However, for both mouse strains it was 
not correlated to serotonin, 5-HT and 5-hydroxyindole acetic acid concentrations, unlike the 
metabolites in the NAD biosynthesis and xanthurenic pathways, suggesting the latter two 
pathways are in part regulated by the total concentration of tryptophan. For the NOD-E mice 
the pathway from kynurenine to xanthurenic acid was more pronounced than that found in 
NOD mice, while correlations were more evenly spread across metabolites including 
anthranilic acid and quinolinic acid for NOD mice. 
 
 
Figure 5. A: Pearson correlation plots for the tryptophan pathway for NOD and NOD-E mice. 
Correlations were calculated for each pair of metabolites with the circle representing the 
magnitude of the correlation coefficient. B: The tryptophan pathway mapped in the 
correlation analysis in A. Key: 5-HT 5-hydroxytryptophan, 5-HIAA 5-Hydroxyindole acetic 
acid. 
 
Alterations in metabolism in the pancreas using lipidomics: 
Our lipidomic analysis was applied to the pancreas samples to further investigate whether 
blood plasma based biomarkers reflected changes in the pancreas across the mouse 
models examined. For the positive ionisation mode analysis of the pancreas extracts (Figure 
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6a), 470 variables were detected across the dataset and these were imported into the 
multivariate models. Examining samples from mice regardless of age, again, the samples 
from the NOD, NOD-E and NOD-SCID mice were compared and OPLS-DA readily 
separated the three mouse genotypes according to their lipidomic profiles (Figure 6b) 
demonstrating the profound difference between the three mouse models. This model was 
improved by a two group comparison where the NOD-SCID mice were compared with a 
combined group of NOD and NOD-E mice (Figure 6c), although one must be aware of the 
relatively small number of NOD-SCID animals in this comparison. This was in part driven by 
increased concentrations of sphingomyelins SM(d34:2) (m/z = 701.558, [M+H]+) and 
SM(d38:2) (m/z = 757.621, [M+H]+],  SM(d40:2) (m/z = 785.652, [M+H]+) and the 
sphingolipid Cer (t34:0) (m/z = 594.581, [M+K]+]) in the pancreas tissue of NOD-SCID mice, 
and increases in the concentrations of TG (46:1) (m/z = 815.636, [M+K]+), PC (33:4) (m/z = 
762.506, [M+Na]+), PC (34:2) (m/z = 758.567, [M+H]+), MG (16:0) (m/z = 313.272, [M+H-
H2O]
+  and unknown m/z = 760.135 in the NOD and NOD-E mice. 
Excluding samples from the NOD-SCID mice from the analysis, pancreas tissue from NOD 
and NOD-E mice could readily be distinguished (Figure 6d).  This was driven by increases 
in the concentration of lipids PE (O-36:5), (m/z = 724.526, [M+H]+), PE (O-32:0),  (m/z = 
700.523, [M+Na]+), PE (P-38:6; (m/z = 748.526, [M+H]+), unknown m/z = 753.558 and 
SM(39:1) (m/z = 773.652, [M+H]+) in the NOD mice and increases in Cer (d34:1) (m/z = 
538.518, [M+H]+), DG (40:3) (m/z = 699.592, [M+H-H2O]
+), TG (48:1) (m/z = 843.681, 
[M+K]+) and DG (40:5) (m/z = 671.565, [M+H]+) lipids in NOD-E mice. 
To further examine the metabolic changes in the pancreas we examined NOD and NOD-E 
mice aged 16 weeks of age and older, comparing NOD mice that had either developed or 
not developed diabetes. However, no model could be built that discriminated between NOD 
and NOD-E mice, and a combined NOD-E, NOD and NOD non diabetic model, suggesting 
that metabolic differences were most apparent at the earlier time points. To confirm this, a 
robust model was built comparing the lipid profiles of pancreas from mice aged 12 weeks 
and under (Figure 6e). This was caused by increases in TAG (34:1), (m/z = 647.4563, 
[M+K]+); PE-Ceramide (d27:2, putative) (m/z = 583.383, [M+H]+); TAG (46:8), (m/z = 
801.548, [M+H]+) and PE (O-36:5) or PE(P-36:4); (m/z = 724.526, [M+Na]+) and decreases 
in PS(O-40:5) (m/z = 824.588, [M+H]+; PE (30:2),(m/z = 660.421, [M+H]+]), PE (32:2), (m/z 
= 688.451, [M+H]+) and PC (O-38:4), (m/z = 818.601, [M+Na]+) in the pancreas of NOD 
mice. 
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Figure 6. A: High resolution mass spectrum of a typical pancreas extract from the NOD 
mouse. B: OPLS-DA plot of lipidomics of the pancreas comparing NOD (red circles), NOD-E 
(green circles) and NOD-SCID (yellow circles) mice. Data is univariate scaled. R2(X) = 79%, 
R2(Y) = 89%; Q2 = 61%; p = 4.5*10-12 by CV-ANOVA for cross validation. 2 components and 
7 orthogonal components. C: OPLS-DA plot of lipidomics of the pancreas comparing NOD-
SCID mice (yellow circles) compared with the other NOD and NOD-E mice (red circles) 
treated as a single group. R2(X) = 74%; R2(Y) = 92%; Q2 = 79%; p = 1.3*10-13, 1 component 
and 4 orthogonal components. D. OPLS-DA plot of lipidomics of the pancreas comparing 
NOD (red circles) and NOD-E (green circles) mice across all ages. R2(X) = 76%; R2(Y) = 
92%; Q2 = 60%; p = 7.6*10-9, 1 component and 6 orthogonal components. E. OPLS-DA plot 
of lipidomics of the pancreas comparing NOD and NOD-E mice under 14 weeks of age. 
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R2(X) = 49%; R2(Y) = 81%; Q2 = 63%; p = 5.2*10-8, 1 component and 2 orthogonal 
components. 
 
Alterations in amino acid metabolism in the pancreas: 
Repeating the amino acid based assay analysis for the pancreas, again the pancreas of the 
NOD-SCID mice were significantly different from the other two mouse models either treating 
all three models as distinct groups (data not shown) or comparing the NOD-SCID mice with 
a combined group of NOD and NOD-E mice (Figure 7a). This was driven by increases in 
riboflavin, thiamine, anthranilic acid, methionine and dimethylglycine in the NOD-SCID mice 
and increases in phosphocholine, 3-phosphoserine, creatine, cytosine and cytidine in the 
other two strains. Similar results were produced when the data was Pareto scaled (Figure 
7b).  
Repeating the analysis but comparing the NOD and NOD-E mice another robust OPLS-DA 
was built (R2(X) = 42%; R2(Y) = 99%; Q2 = 70%; CV-ANOVA p = 0.04; Figure 7c). The 
pancreas from NOD mice had increased concentrations of alanine (p = 0.003 for a Student’s 
T-test univariate analysis), asparagine (p = 0.03), xanthine, NADH, arginosuccinate and 
glucose while the pancreas from NOD-E mice were most characterised by relative increases 
in a range of aromatic amino acids including indole (p = 0.004), xanthurenate (p = 0.002), 
tryptophan (p = 0.001), S-adenosyl homocysteine (p = 0.0006), 5-HT (p = 0.0004) and 
serotonin (p = 0.0002) as well as methionine (p = 000003). S-adenosyl homocysteine, 5-HT, 
serotonin and methionine also passed the threshold for Bonferroni correction (p = 0.00047). 
Similar results were produced when the data was Pareto scaled (Figure 7d).  
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Figure 7: A: OPLS-DA plot of targeted core metabolism of extracts of pancreas tissue 
comparing the NOD-SCID mouse (green circles) to a combined group of NOD and NOD-E 
mice (red circles), regardless of age. Data is univariate scaled. R2(X) = 37%; R2(Y) = 96%; 
Q2 = 82%; CV-ANOVA p = 2.8*10-6, 1 component and 2 orthogonal components. B: S-plot of 
most discriminatory metabolites in a Pareto scaled OPLS-DA model using the data analysed 
in A.  C: OPLS-DA plot of targeted core metabolism of extracts of pancreas tissue 
comparing the NOD mouse (red circles) to NOD-E mice (green circles), regardless of age. 
Data is univariate scaled. R2(X) = 42%; R2(Y) = 99%; Q2 = 70%; CV-ANOVA p = 0.04, 
1component and 2 orthogonal components. D: S-plot of most discriminatory metabolites in a 
Pareto scaled OPLS-DA model using the data analysed in C.   
 
Modelling correlated metabolism between blood plasma and the pancreas 
To examine whether metabolic changes in the pancreas manifested themselves in blood 
plasma, OPLS was used to regress changes in aqueous metabolism in the pancreas against 
the same metabolites detected in blood plasma across 23 week old NOD, NOD-E and NOD-
SCID mice. Applying this approach to all the mouse models a weak OPLS model was built (2 
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components and 2 orthogonal X components; R2(X) = 53%; R2(Y) = 54%; Q2 = 8%; 
Supplementary Figure 1a). The most correlated metabolite between the two tissues was 
betaine (p = 0.005) and β-hydroxyisovalerate (p = 0.007). Next we examined correlations 
within individual strains. While no model could be built for the NOD-SCID mice and only a 
poor model for the NOD mice was produced (2 components and no orthogonal components; 
R2(X) = 55%; R2(Y) = 60%; Q2 = 16%), a robust model was built for NOD-E mice (3 
components, 3 orthogonal X components and 3 orthogonal Y components; R2(X) = 99%; 
R2(Y) = 99%; Q2 = 100%). This was driven by changes in the correlation of serine (p = 
0.046), citrulline (p = 0.030), taurine (p = 0.033), aminoisobutyric acid (p = 0.042), 
homocysteine (p = 0.039), GABA (p = 0.046), histamine (p = 0.024), 3-hydroxyanthranilic 
acid (p = 0.03), betaine (p = 0.032), α-glycerophosphocholine (p = 0.048), creatine (p = 
0.036), cytosine (p = 0.02), xanthosine (p = 0.034), beta-hydroxyisovaleric acid (p = 0.03), 
adenine (p = 0.04), cytidine (p = 0.044), SAH (p = 0.41), N-acetylglutamate (p = 0.036, N-
acetylglutamine (p = 0.038) (Supplementary Figure 1b). 
Examining changes in the gut metabolome 
To investigate whether changes in the mouse metabolome could be related to alterations in 
the gut metabolome we examined the metabolite composition of faeces from NOD and 
NOD-E mice using GC-MS to examine the total fatty acid compliment and LC-MS/MS to 
examine the aqueous metabolome. While no PLS-DA or OPLS-DA models could be built 
separating the spectral profiles at 6 weeks or 12 weeks of age (n=6 for both groups), a time 
trend was detected using PLS considering either all mice (for total fatty acids: 2 components; 
R2(X) = 0.42, R2(Y) = 0.56, Q2 = 0.25); for aqueous metabolites: 4 components, R2(X) = 0.71, 
R2(Y) = 0.88, Q2 = 0.37) (data not shown) or NOD mice (for total fatty acids: 2 components 
R2(X) = 0.45, R2(Y) = 0.88, Q2 = 0.62; for aqueous metabolites: 2 components, R2(X)=0.55, 
R2(Y) = 0.74, Q2 = 0.38) (Supplementary figure 2). For the NOD mice this was driven by an 
increase in C14:1, C18:3n-6 and C18:3n-3 fatty acids, serotonin, guanosine, creatine and 
trimethylamine, and a decrease in C16:0, C18:0 and C20:0 fatty acids, ADMA, taurine, 
citrate and α-ketoisocaproic acid. 
 
Discussion: 
The NOD mouse and its related strains have been major research tools for 
understanding how T1DM arises across the natural life course of the animal 38. The mouse 
develops a number of autoantibodies as it ages including those recognising autoantigens 
insulin, IA-2 and glutamic acid decarboxylase that, as in humans, provide markers of 
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ongoing beta cell destruction. The NOD mouse has been the subject of a number of 
previous metabolomic studies which have used the reproducible time course and incidence 
of T1DM  in this model to follow metabolic changes that accompany the development of 
T1DM 16,18,39-41. However, these studies have focussed solely on NOD mice, and thus it is 
difficult to disentangle any metabolic changes that are associated with ageing in the animal 
from the subsequent age related changes associated with the development of T1DM. To 
address this Fahrmann and colleagues 18 compared NOD mice that developed T1DM with 
those that did not across the time course. In the present study we took an alternative 
strategy and compared the metabolic profiles of blood plasma and pancreatic tissue from 
NOD, NOD-E and NOD-SCID mice, the latter two strains being protected from the 
development of T1DM compared with NOD mice. 
We compared both lipid and aqueous metabolism changes in both blood plasma and 
pancreas tissue across the three mouse models, and a striking result was the discrimination 
of NOD-SCID mice from the NOD and NOD-E strains. In terms of both intact lipids and the 
core metabolic pathways measured in our aqueous assays, NOD-SCID mice were readily 
discriminated from the other two strains and in cross validation of the associated pattern 
recognition models, NOD-SCID mice could be classified with 100% success according to 
their metabolic profiles regardless of age. The profound metabolic differences, which 
discriminate the NOD-SCID mice from the other two strains indicate that this model is a poor 
control strain to compare with NOD mice when considering the metabolic changes that 
accompany T1DM. As a result we have focussed on the discrimination between NOD and 
NOD-E mice in terms of the metabolic changes that accompany the development of T1DM. 
We focussed on female mice given the sexual dimorphism of the risk of developing T1DM. 
Females mice are more likely to develop T1DM and this is thought to be due to both a sex-
specific, epistatic interaction with Idd4.1 in females 42 and differential interactions with the gut 
microflora in male and female NOD mice 43. 
Across both lipid and aqueous metabolites datasets in both blood plasma and the 
pancreas we could discriminate NOD and NOD-E mice readily, and indeed in NOD mice 
younger than 14 weeks, and hence prior to the onset of T1DM, it was possible to 
discriminate mice according to their lipid and aqueous profiles from the NOD-E strain. 
Examining the RIP CD154 x RAG-/- mouse, a different model for T1DM produced by 
expressing CD154 under the rat insulin promoter crossed into the immuno-deficient 
recombination-activating gene (RAG) knockout mouse, Overgaard and colleagues have also 
shown that metabolic changes pre-date the development of overt T1DM. Indeed some of the 
metabolic changes were similar between the CD154 x RAG-/- mouse and the NOD mouse 
with decreases in lysophosphatidylcholines and decreased methionine (detected in the 
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pancreas of NOD mice), as well as increases in ceramides in the CD154 x RAG-/- mouse 15. 
Indeed, La Torre and colleagues have even detected decreases in phosphatidylcholines and 
phosphatidylethanolamines in cord blood of children at birth who subsequently go on to 
develop T1DM compared with children matched for HLA risk, sex, date of birth and 
gestational age but who do not develop the disease 17,44. However, it was not possible to 
discriminate between NOD mice that did not develop autoimmune diabetes from NOD-E 
mice at 25-30 weeks, suggesting that metabolism normalises for those NOD mice that avoid 
autoimmune diabetes in the normal disease aetiology. 
In terms of different classes of metabolites, one of the biggest changes was 
associated with amino acid metabolism, both in terms of discrimination of the three strains of 
mice and the progression of the disease in NOD mice. Alterations in amino acid metabolism 
have been reported in a number of previous studies. Lu and co-workers have previously 
identified alterations in 5-oxoproline, glutamate and homocysteine as being common to 
T1DM, type 2 diabetes (T2DM) and fulminant type 1 diabetes in patients compared with a 
control group 45. Deja and co-workers correlated increased concentrations of alanine and 
valine with increased concentrations of glycated haemoglobin (HbA1c) using 1H NMR 
spectroscopy of urine 46. Indeed, alterations in amino acid metabolism appears to be a 
central feature of both T2DM and other rarer forms of diabetes. Perhaps the most robust 
metabolic markers for predicting future T2DM incidence are branch chain amino acids, and 
Patel and colleagues, investigating A-β+ ketosis-prone diabetes using stable isotope 
techniques to follow metabolic flux noted that although sufferers had normal oxidation rates 
of fatty acids and acetyl-CoA, there was increased leucine oxidation, conversion of 
glutamine to glutamate but impaired conversion of glutamate to 2-oxoglutarate and reduced 
flux into the citrulline cycle 47. In the present study blood plasma from NOD mice were 
characterised by increases in arginosuccinate and a reduction in ornithine, similarly 
indicating alterations in the citrulline cycle consistent with a reduction in urea production. The 
turnover of the citrulline cycle, and in particular metabolites around arginine, suggests that 
there may be increased NO production and could be associated with activated macrophages 
and subsequent pathology. Xanthine, a purine breakdown product and a precursor for uric 
acid, was also found to be increased in the pancreas of NOD mice. Increased purine 
catabolism and the induction of xanthine oxidase has previously been linked to T1DM 
associated diabetic nephropathy in streptozotocin-dosed rats, presumably through the 
generation of ROS species in the kidneys 48. Further evidence of dysfunction in the kidneys 
is suggested by the increased creatinine concentrations in the blood plasma of NOD mice in 
the present study.   
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It has previously been observed that nicotinamide has the ability to both prevent 
T1DM in prediabetic NOD mice and reverse the pathology in mice that exhibit hyperglycemia 
38, and one of the major changes detected in both the pancreas and blood plasma in the 
current study involved changes in the precursors of nicotinamide, NAD+ and NADP+. This 
included an increase in the niacin precursor kynurenic and decreases in serotonin and 5-HT 
in blood plasma of NOD mice and increases in xanthinine and NADH, and decreases in 
xanthurenate in the pancreas of NOD mice. The tryptophan pathway produces either 
kynurenic acid via indoleamine 2,3-dioxygenase (IDO) which ultimately can be used to 
synthesize NAD+ for energy generation, or 5-HT and serotonin via tryptophan hydroxylase, 
which can be used to synthesize melatonin (Figure 5b). Considering the three pathways that 
branch off tryptophan, while NOD-E mice demonstrated high correlations between 
kynurenine, kynurenic acid and xanthurenic acid, the correlation profiles were more equally 
spread across metabolites derived from tryptophan, including the NAD-synthesis pathway. 
This suggests that different regulatory mechanisms are in operation between the two mouse 
strains. While no mechanism has been identified that links increased nicotinamide 
metabolism to the development of T1DM in the NOD mouse, the generation of reactive 
oxygen species in mitochondria, mitochondrial DNA damage and genetic interactions with 
variants in nicotinamide adenine dinucleotide hydrogen dehydrogenase subunit 2 have all 
been linked to increased relative risk of T1DM in the NOD mouse 38. Furthermore, 
inflammation is known to stimulate the expression of IDO in dendritic cells to increase 
kynurenic acid concentration 49, and alterations in this pathway have previously been 
detected in patients with T1DM 50. In addition, the tryptophan pathway has been highlighted 
in a number of chronic diseases as well as ageing 51. 
Fahrmann and colleagues 18 previously described how changes in ROS species and 
their associated products accompany the development of T1DM in the NOD mouse. While 
we did not find changes in the production of ROS products, such as oxidized amino acids 
and nucleotides, in the present study a reduction in methionine was detected in the pancreas 
of NOD mice suggesting they may have increased oxidative stress compared with NOD-E 
mice. 
 A wide range of lipid species were altered across the three strains and across the 
time courses, and a number of previous studies have highlighted altered lipid metabolism 
both pre and post overt T1DM 8,17,52,53. Alterations in lipid metabolism in female NOD mice 
has previously been reported by Markle and colleagues 23 who reported alterations in 
sphingolipid metabolism in female NOD mice who have a higher incidence of T1DM 
compared with male mice. These changes could be corrected if the female mice were given 
a faecal transplant from male mice, indicating these changes were in part driven by the gut 
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microflora. However, sphingolipids are not found in bacteria, suggesting the lipid changes 
were a downstream effect rather than something that directly acts on sphingolipid 
metabolism. Furthermore, Makinen and colleagues have also suggested altered sphingolipid 
metabolism in patients with type 1 diabetes-associated kidney disease 54. While we did not 
detect changes in sphingolipid metabolism in blood plasma, there were a number of 
sphingolipid species altered in the pancreas – being one of the classes of lipids that most 
readily discriminated NOD-SCID from NOD and NOD-E mice. In addition SM(39:1) was 
increased in the pancreas of NOD mice and Cer (d34:1) in the pancreas of NOD-E mice. 
 In blood plasma, the NOD mice were clearly characterised by increases in 
triglycerides containing longer, polyunsaturated fatty acids, and relative decreases in 
lysophospholipids containing longer polyunsaturated acids as well as cholesterol esters. 
Alterations in phospholipids, especially lysophospholipids, and cholesterol esters have 
previously been described in T1DM with well controlled diabetes compared with healthy 
controls 17,52,55,56, with Fievet and colleagues explaining this as arising from lipoprotein 
remodelling and an increased pro-inflammatory state for those with T1DM. Indeed, in 
children autoantibodies to a number of lysophospholipids have also been described 57, 
demonstrating the interplay between this class of lipid and autoimmune disease. 
Conclusions: 
In summary, we have used a combination of lipidomics and metabolomics to profile the 
development of T1DM in the NOD mouse and compare these changes with NOD-E and 
NOD-SCID mice, two strains that are protected from T1DM. This approach has highlighted 
that the NOD-SCID mouse provides a poor control for the NOD mouse in terms of metabolic 
changes, and indeed the most profound metabolic differences between the mouse strains 
were between NOD-SCID and the other two strains, regardless of diabetic status, 
underlining how different the NOD-SCID mice are. When comparing the NOD and NOD-E 
mice the most consistent metabolic changes are in the tryptophan pathway and in particular 
in the synthesis of kynurenic acid derivatives, and a reduction in lysophospholipids. Both 
pathways have previously been implicated in modulating immune responses, underlying the 
interplay between metabolism and inflammation. As well as highlighting metabolic 
mechanisms that could be targeted to treat T1DM, such metabolic markers of disease could 
be used in the future to target immune-suppression therapies to reduce the likelihood of 
developing T1DM in at risk populations.  
 
Supporting Information: 
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The following files are available free of charge at ACS website http://pubs.acs.org:  
Supplementary Data_NOD_mouse_paper: This file contains a detailed description of the 
mice used in this study, supplementary figures 1-2 and supplementary tables. 
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Figure legends 
Figure 1: A: High resolution mass spectrum of a typical lipid extract from blood plasma 
derived from the NOD mouse. B. OPLS-DA plot of lipidomics of blood plasma from NOD, 
NOD-E and NOD-SCID mice considered as separate groups. Data is Pareto scaled. R2(X) = 
75%, R2(Y) = 48%; Q2 = 34%; p = 3.5*10-22 by CV-ANOVA for cross validation. 2 
components and 6 orthogonal components. C. OPLS-DA plot of lipidomics of blood plasma 
from NOD-SCID mice compared with a combined group of NOD and NOD-E mice (labelled 
Both). Data is Pareto scaled. R2(X) = 69%; R2(Y) = 68%; Q2 = 51%; p = 5.8*10-34. 1 
component and 6 orthogonal components. D. OPLS-DA plot of lipidomics of blood plasma 
from NOD and NOD-E mice. Data is Pareto scaled. R2(X) = 57%, R2(Y) = 41%, Q2 = 23%; p 
= 5.4*10-9, 1 component and 3 orthogonal components. E. OPLS-DA plot of lipidomics of 
blood plasma from NOD and NOD-E mice under 14 weeks of age. Data is Pareto scaled. 
R2(X) = 43%, R2(Y) = 32%, Q2 = 23%, p = 1.2*10-7, 1 component and 1 orthogonal 
component. F. OPLS-DA plot of lipidomics of blood plasma from NOD and NOD-E mice 
aged 14 weeks and over. Data is Pareto scaled. R2(X) = 56%, R2(Y) = 80%, Q2 = 54%; 
p=2.2*10-5, 1 component and 4 orthogonal components. G. OPLS-DA plot of lipidomics of 
blood plasma from NOD (diabetic) and NOD (non-diabetic referred to as NODSTAR) mice 
aged 25-30 weeks and over. R2(X) = 68%; R2(Y) = 79%; Q2 = 56%; p = 2.5*10-11, 1 
component and 4 orthogonal components. 
 
Figure 2: A. OPLS-DA plot of total fatty acid analysis of blood plasma from NOD, NOD-E 
and NOD-SCID mice considered as separate groups. Data is Univariate scaled. R2(X) = 
25%; R2(Y) = 47%; Q2 = 33%. B. OPLS-DA plot of total fatty acid analysis of blood plasma 
from NOD-SCID mice compared with a combined group of NOD and NOD-E mice (labelled 
Both). Data is univariate scaled. R2(X) = 40%; R2(Y) = 80%; Q2 = 72%; p = 6.3*10-37. C. S-
plot of Pareto scaled variables from the dataset analysed for the plot in B. D. PLS plot of age 
against metabolic profile of NOD mice. Q2 = 51%, R2(X) = 27%, R2Y = 77%; p=4*10-6. 
 
Figure 3: A. OPLS-DA plot of targeted analysis of central metabolism (amino acids, TCA 
cycle intermediates, nucleotides, and other small aqueous metabolites) of blood plasma from 
NOD, NOD-E and NOD-SCID mice considered as separate groups. Data is Univariate 
scaled. R2(X) = 56%, R2(Y) = 72%, Q2 = 52%, 2 components and 4 orthogonal components; 
CV ANOVA validation p = 1.5*10-22. B. OPLS-DA plot of targeted analysis of central 
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metabolism of blood plasma from NOD-SCID mice compared with the NOD and NOD-E 
mice as a single group. R2(X) = 42%, R2(Y) = 79%, Q2 = 79%, 1 component and 2 
orthogonal components; CV-ANOVA validation p = 2.7*10-38. C. Variable Importance 
Parameter (VIP) plot to show key metabolites that are most important for the discrimination 
for the plot in B. D. OPLS-DA plot of targeted analysis of central metabolism of blood plasma 
from NOD and NOD-E mice. Data is Univariate scaled. R2(X) = 51%; R2(Y) = 76%; CV-
ANOVA validation p = 2*10-10. E. VIP plot to show key metabolites that are most important 
for the discrimination for the plot in D. F. OPLS-DA plot of targeted analysis of central 
metabolism of blood plasma from NOD and NOD-E mice below 14 weeks of age. Data is 
Univariate scaled. R2(X) = 44%, R2(Y) = 84%, Q2 = 74%, 1 component and 2 orthogonal 
components; CV ANOVA validation p = 2.7*10-38. G. OPLS-DA plot of targeted analysis of 
central metabolism of blood plasma from NOD and NOD-E mice 14 weeks and older of age. 
Data is Univariate scaled. R2(X) = 64%, R2(Y) = 82%, Q2 = 51%, 1 component and 4 
orthogonal components; CV-ANOVA validation p = 2.7*10-38. H. SUS-plot of discriminatory 
metabolites for models described in F and G.  
 
Figure 4. A: PLS model of targeted analysis of central metabolism of blood plasma from 
NOD mice against age (R2X = 53%, R2Y = 79%, Q2 = 65%). B: SUS-plot of PLS models for 
NOD mice and NOD-E mice against age. In this plot the loadings for the two PLS models are 
plotted against each other so that if the two models had the same loadings then these would 
line up at 45° to the x and y-axes. While some metabolites are in common there is also a 
degree of scatter from the 45° line showing that other metabolites are responsible for the 
ageing trends in the NOD and NOD-E mice. 
 
Figure 5. A: Pearson correlation plots for the tryptophan pathway for NOD and NOD-E mice. 
Correlations were calculated for each pair of metabolites with the circle representing the 
magnitude of the correlation coefficient. B: The tryptophan pathway mapped in the 
correlation analysis in A. Key: 5-HT 5-hydroxytryptophan, 5-HIAA 5-Hydroxyindole acetic 
acid. 
 
Figure 6. A: High resolution mass spectrum of a typical pancreas extract from the NOD 
mouse. B: OPLS-DA plot of lipidomics of the pancreas comparing NOD (red circles), NOD-E 
(green circles) and NOD-SCID (yellow circles) mice. Data is univariate scaled. R2(X) = 79%, 
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R2(Y) = 89%; Q2 = 61%; p = 4.5*10-12 by CV-ANOVA for cross validation. C: OPLS-DA plot 
of lipidomics of the pancreas comparing NOD-SCID mice (yellow circles) compared with the 
other NOD and NOD-E mice (red circles) treated as a single group. R2(X) = 74%; R2(Y) = 
92%; Q2 = 79%; p = 1.3*10-13. D. OPLS-DA plot of lipidomics of the pancreas comparing 
NOD (red circles) and NOD-E (green circles) mice across all ages. R2(X) = 76%; R2(Y) = 
92%; Q2 = 60%; p = 7.6*10-9. E. OPLS-DA plot of lipidomics of the pancreas comparing NOD 
and NOD-E mice under 14 weeks of age. R2(X) = 49%; R2(Y) = 81%; Q2 = 63%; p = 5.2*10-8.  
 
Figure 7: A: OPLS-DA plot of targeted core metabolism of extracts of pancreas tissue 
comparing the NOD-SCID mouse (green circles) to a combined group of NOD and NOD-E 
mice (red circles), regardless of age. Data is univariate scaled. R2(X) = 37%; R2(Y) = 96%; 
Q2 = 82%; CV-ANOVA p = 2.8*10-6. B: S-plot of most discriminatory metabolites in a Pareto 
scaled OPLS-DA model using the data analysed in A.  C: OPLS-DA plot of targeted core 
metabolism of extracts of pancreas tissue comparing the NOD mouse (red circles) to NOD-E 
mice (green circles), regardless of age. Data is univariate scaled. R2(X) = 42%; R2(Y) = 99%; 
Q2 = 70%; CV-ANOVA p = 0.04. D: S-plot of most discriminatory metabolites in a Pareto 
scaled OPLS-DA model using the data analysed in C.   
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